Sinohealth Holdings Ltd (2361) Fair Value & Analysis
Healthcare · HK · Market cap HK$2.0B
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 3 days ago
Fair value updated Aug 13, 2026, revised from HK$4.61 to HK$4.62 (+0.2%) since Aug 6, 2026. Share price +0.2% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range (HK$3.06 to HK$6.41) leaves room in how you read the outcome.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
49‑month range HK$1.94 – HK$6.33 · fair‑value band HK$3.06 – HK$6.41 · the HK$5.09 price screens above the HK$4.62 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Sinohealth Holdings Ltd (2361) currently trades at HK$5.09, while our model-based Fair Value estimate is HK$4.62, implying the stock looks roughly 9.2% fairly valued today. The Quality Score stands at 74/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Sinohealth Holdings Ltd generated revenue of HK$419M at a net margin of 22.3%. Revenue grew 11.0% year over year. It earns a return on equity of 12.9%. The stock trades on a trailing P/E of 20.8 (as of Jul 2, 2026). Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$3.06 (bear case) to HK$6.41 (bull case); at HK$5.09, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 8% below its 52-week high and 77% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -64% fair-value upside, at -9%, 2361 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (HK$4.17) versus Asset-Based (HK$1.24). Highest evidence: Residual Income (76).
Notify me when 2361 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 70 · Market factors (momentum, volatility) 70
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Sinohealth Technology Holdings Limited provides healthcare solutions for sales and marketing needs of medical product manufacturer clients in Mainland China and internationally.
Full company description
Sinohealth Technology Holdings Limited provides healthcare solutions for sales and marketing needs of medical product manufacturer clients in Mainland China and internationally. It engages in the research and development, and provision of data insight solutions, data-driven publications and events, and software as a service (SaaS) products; research and development, and operation of Smart Medical Cloud under the business line of SaaS products; management of marketing and promotion services of medicine; operation of SaaS products; provision of internet information and internet data center services; production and publication of videos; and foreign-related market research business. The company also offers precision marketing solutions; and consulting and marketing services. It serves various fields, such as pharmaceutical industry, retail pharmacies, and physical examination and hospitals. Sinohealth Technology Holdings Limited was formerly known as Sinohealth Holdings Limited and changes its name to Sinohealth Technology Holdings Limited in February 2026. The company was founded in 2007 and is headquartered in Guangzhou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sinohealth Holdings Ltd reported revenue of HK$419M in FY2025 versus HK$324M in FY2021, a compound +6.6%/yr. Reported net income was HK$93.4M in FY2025, compounding +4.3%/yr from FY2021.
Watch 2361: get an alert when its fair value changes →
Peer Group
Health Information Services · 125 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $241.51 | $91.49 | -62% |
| Pro Medicus Limited PME | A$183.71 | A$23.74 | -87% |
| BrightSpring Health Services, Inc BTSG | $59.68 | $21.31 | -64% |
| HealthEquity, Inc HQY | $105.50 | $56.63 | -46% |
| Hinge Health, Inc HNGE | $86.32 | $24.03 | -72% |
| 10x Genomics, Inc TXG | $58.48 | $17.18 | -71% |
| Waystar Holding WAY | $24.54 | $12.86 | -48% |
| XtalPi Holdings 2228 | HK$8.19 | HK$1.04 | -87% |
| Doximity, Inc DOCS | $24.99 | $25.91 | +4% |
| Privia Health Group PRVA | $21.54 | $5.26 | -76% |
Compare Sinohealth Holdings Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sinohealth Holdings Ltd (2361) overvalued or undervalued?
What is the fair value of 2361?
What is the quality score of 2361?
What is the revenue of Sinohealth Holdings Ltd (2361)?
What is the net profit margin of 2361?
Does Sinohealth Holdings Ltd pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Sinohealth Holdings Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.